89bio (ETNB) Financials

$9.23 +0.20 (+2.24%)

As of 01:35 PM Eastern

Annual Income Statements for 89bio

This table shows 89bio's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Net Income / (Loss) Attributable to Common Shareholders	-367	-142	-102
Consolidated Net Income / (Loss)	-367	-142	-102
Net Income / (Loss) Continuing Operations	-367	-142	-102
Total Pre-Tax Income	-366	-138	-102
Total Operating Income	-385	-151	-102
Total Gross Profit	0.00	0.00	0.00
Total Revenue	0.00	0.00	0.00
Total Cost of Revenue	0.00	0.00	0.00
Total Operating Expenses	385	151	102
Selling, General & Admin Expense	40	29	21
Research & Development Expense	345	122	81
Total Other Income / (Expense), net	18	13	0.24
Interest Expense	5.29	4.79	1.92
Other Income / (Expense), net	24	18	2.16
Income Tax Expense	0.69	3.87	0.02
Basic Earnings per Share	($3.51)	($2.00)	($2.93)
Weighted Average Basic Shares Outstanding	104.71M	71.17M	34.81M
Diluted Earnings per Share	($3.51)	($2.00)	($2.93)
Weighted Average Diluted Shares Outstanding	104.71M	71.17M	34.81M
Weighted Average Basic & Diluted Shares Outstanding	145.98M	93.50M	52.23M

This table shows 89bio's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	-71	-120	-147	-48	-52	-40	-35	-39	-29	-25	-27
Consolidated Net Income / (Loss)	-71	-118	-149	-48	-52	-40	-35	-38	-29	-25	-27
Net Income / (Loss) Continuing Operations	-71	-118	-149	-48	-52	-40	-35	-38	-29	-25	-27
Total Pre-Tax Income	-71	-118	-149	-48	-52	-36	-35	-38	-29	-25	-27
Total Operating Income	-76	-122	-152	-53	-57	-41	-39	-42	-29	-25	-27
Total Gross Profit	0.00	-	0.00	0.00	0.00	-	0.00	0.00	0.00	-	0.00
Total Revenue	0.00	-	0.00	0.00	0.00	-	0.00	0.00	0.00	-	0.00
Total Cost of Revenue	0.00	-	0.00	0.00	0.00	-	0.00	0.00	0.00	-	0.00
Total Operating Expenses	76	122	152	53	57	41	39	42	29	25	27
Selling, General & Admin Expense	12	11	10	8.57	9.85	7.61	7.93	7.21	6.22	6.30	4.84
Research & Development Expense	64	111	141	45	47	34	31	35	22	19	22
Total Other Income / (Expense), net	4.77	3.91	3.07	5.60	5.69	4.84	4.62	3.74	-0.31	0.78	0.24
Interest Expense	1.27	1.19	2.36	0.87	0.86	0.87	0.96	0.89	2.08	0.55	0.54
Interest & Investment Income	0.00	-	0.00	0.00	0.00	-	0.00	0.00	0.00	-	0.00
Other Income / (Expense), net	6.04	5.10	5.43	6.47	6.56	5.70	5.58	4.63	1.76	1.32	0.77
Income Tax Expense	0.14	0.26	0.20	0.13	0.10	3.87	0.00	0.00	0.00	0.02	0.00
Basic Earnings per Share	($0.49)	($1.10)	($1.39)	($0.48)	($0.54)	($0.49)	($0.45)	($0.52)	($0.54)	$0.13	($0.57)
Weighted Average Basic Shares Outstanding	146.37M	104.71M	107.08M	99.83M	95.85M	71.17M	76.34M	74.13M	53.17M	34.81M	47.25M
Diluted Earnings per Share	($0.49)	($1.10)	($1.39)	($0.48)	($0.54)	($0.49)	($0.45)	($0.52)	($0.54)	$0.13	($0.57)
Weighted Average Diluted Shares Outstanding	146.37M	104.71M	107.08M	99.83M	95.85M	71.17M	76.34M	74.13M	53.17M	34.81M	47.25M
Weighted Average Basic & Diluted Shares Outstanding	145.98M	145.98M	106.13M	105.91M	98.38M	93.50M	75.64M	75.48M	72.87M	52.23M	46.54M

This table details how cash moves in and out of 89bio's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Net Change in Cash & Equivalents	-190	261	2.80
Net Cash From Operating Activities	-368	-129	-81
Net Cash From Continuing Operating Activities	-368	-129	-81
Net Income / (Loss) Continuing Operations	-367	-142	-102
Consolidated Net Income / (Loss)	-367	-142	-102
Depreciation Expense	0.04	0.05	0.07
Amortization Expense	-9.14	-5.37	-0.22
Non-Cash Adjustments To Reconcile Net Income	23	18	11
Changes in Operating Assets and Liabilities, net	-15	0.78	11
Net Cash From Investing Activities	-41	-123	-34
Net Cash From Continuing Investing Activities	-41	-123	-34
Purchase of Property, Plant & Equipment	-0.02	-0.00	-0.01
Purchase of Investments	-376	-341	-153
Sale and/or Maturity of Investments	335	218	119
Net Cash From Financing Activities	219	513	118
Net Cash From Continuing Financing Activities	219	513	118
Repayment of Debt	0.00	-21	0.00
Repurchase of Common Equity	-0.25	0.00	0.00
Issuance of Debt	9.35	24	0.00
Issuance of Common Equity	158	496	117
Other Financing Activities, net	52	14	1.09
Cash Interest Paid	3.14	2.59	1.08

This table details how cash moves in and out of 89bio's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Change in Cash & Equivalents	189	35	-121	-5.36	-99	64	6.49	-105	296	-17	12
Net Cash From Operating Activities	-72	-122	-145	-61	-40	-34	-30	-34	-30	-27	-15
Net Cash From Continuing Operating Activities	-72	-122	-145	-61	-40	-34	-30	-34	-30	-27	-15
Net Income / (Loss) Continuing Operations	-71	-118	-149	-48	-52	-40	-35	-38	-29	-25	-27
Consolidated Net Income / (Loss)	-71	-118	-149	-48	-52	-40	-35	-38	-29	-25	-27
Depreciation Expense	0.01	0.01	0.01	0.01	0.01	0.02	0.01	0.01	0.01	0.02	0.02
Amortization Expense	-1.44	-1.76	-2.31	-2.42	-2.66	-1.77	-1.87	-0.91	-0.82	-0.26	-0.24
Non-Cash Adjustments To Reconcile Net Income	7.16	5.42	6.83	5.46	5.17	4.14	4.42	4.18	4.80	2.43	2.76
Changes in Operating Assets and Liabilities, net	-6.19	-6.90	-0.82	-16	9.44	3.55	1.80	0.67	-5.24	-4.68	9.45
Net Cash From Investing Activities	-7.83	20	-8.64	28	-80	-64	38	-102	4.11	-11	-42
Net Cash From Continuing Investing Activities	-7.83	20	-8.64	28	-80	-64	38	-102	4.11	-11	-42
Purchase of Property, Plant & Equipment	-0.07	-0.02	-	-	0.00	-0.00	-	-	0.00	-0.00	-
Purchase of Investments	-105	-63	-83	-78	-152	-124	-36	-147	-34	-43	-69
Sale and/or Maturity of Investments	97	83	74	106	72	61	75	45	38	32	27
Net Cash From Financing Activities	269	136	33	28	21	162	-1.48	31	322	21	69
Net Cash From Continuing Financing Activities	269	136	33	28	21	162	-1.48	31	322	21	69
Repayment of Debt	0.00	-	-	-	0.00	-	-	-	-21	-	-
Repurchase of Common Equity	0.00	-0.14	-	0.14	-0.25	-	-	-	0.00	-	-
Issuance of Debt	0.00	-	9.35	-	0.00	-	-	-	24	-	-
Issuance of Common Equity	270	136	-	0.06	21	162	-	24	310	20	69
Other Financing Activities, net	-1.00	0.08	24	28	0.11	0.02	-1.48	7.14	8.27	1.16	-
Cash Interest Paid	0.81	1.08	0.69	0.69	0.68	0.68	0.72	0.66	0.54	0.37	0.30

This table presents 89bio's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Total Assets	479	596	197
Total Current Assets	476	594	196
Cash & Equivalents	126	316	55
Short-Term Investments	314	263	133
Inventories, net	1.57	2.29	0.36
Prepaid Expenses	36	15	7.92
Plant, Property, & Equipment, net	0.02	0.05	0.09
Total Noncurrent Assets	0.64	0.40	0.29
Other Noncurrent Operating Assets	0.64	0.40	0.29
Total Liabilities & Shareholders' Equity	479	596	197
Total Liabilities	78	60	45
Total Current Liabilities	36	30	25
Accounts Payable	15	8.59	13
Accrued Expenses	20	21	12
Other Current Liabilities	0.73	0.50	0.17
Total Noncurrent Liabilities	42	30	20
Long-Term Debt	36	25	20
Other Noncurrent Operating Liabilities	6.04	5.56	0.19
Commitments & Contingencies	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	401	536	152
Total Preferred & Common Equity	401	536	152
Preferred Stock	0.00	0.00	0.00
Total Common Equity	401	536	152
Common Stock	1,225	994	467
Retained Earnings	-825	-457	-315
Accumulated Other Comprehensive Income / (Loss)	0.56	0.19	-0.35

This table presents 89bio's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022
Period end date	3/31/2025	9/30/2024	6/30/2024	3/31/2024	9/30/2023	6/30/2023	3/31/2023	9/30/2022
Total Assets	685	458	582	577	460	493	494	201
Total Current Assets	683	456	580	575	460	492	494	200
Cash & Equivalents	315	91	212	218	252	245	351	72
Restricted Cash	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Short-Term Investments	323	332	319	345	196	233	130	121
Inventories, net	1.41	1.76	1.94	2.12	0.24	0.28	-	0.40
Prepaid Expenses	44	32	48	12	11	14	13	6.51
Plant, Property, & Equipment, net	0.09	0.02	0.03	0.04	0.06	0.07	0.08	0.11
Total Noncurrent Assets	0.59	0.31	0.32	0.39	0.29	0.29	0.61	0.22
Other Noncurrent Operating Assets	0.59	0.31	0.32	0.39	0.29	0.29	0.61	0.22
Total Liabilities & Shareholders' Equity	685	458	582	577	460	493	494	201
Total Liabilities	80	80	67	67	50	51	48	48
Total Current Liabilities	38	39	42	38	25	26	24	34
Accounts Payable	15	19	17	15	11	11	17	14
Accrued Expenses	22	19	19	20	14	15	7.12	13
Other Current Liabilities	0.75	0.74	0.76	0.70	0.18	0.17	0.17	0.17
Total Noncurrent Liabilities	42	41	26	29	25	25	24	14
Long-Term Debt	36	36	20	23	25	24	24	13
Other Noncurrent Operating Liabilities	5.75	5.52	5.21	5.48	0.05	0.10	0.14	0.62
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	605	378	515	511	410	442	446	153
Total Preferred & Common Equity	605	378	515	511	410	442	446	153
Total Common Equity	605	378	515	511	410	442	446	153
Common Stock	1,501	1,083	1,073	1,020	828	825	790	444
Retained Earnings	-896	-706	-557	-509	-417	-382	-344	-291
Accumulated Other Comprehensive Income / (Loss)	0.39	1.27	-0.68	-0.52	-0.55	-0.59	-0.24	-0.44

This table displays calculated financial ratios and metrics derived from 89bio's official financial filings.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Growth Metrics	-	-	-
Revenue Growth	0.00%	0.00%	0.00%
EBITDA Growth	-166.63%	-38.52%	-13.86%
EBIT Growth	-170.43%	-33.41%	-11.71%
NOPAT Growth	-154.40%	-47.88%	-13.94%
Net Income Growth	-158.16%	-39.37%	-13.21%
EPS Growth	-75.50%	31.74%	34.60%
Operating Cash Flow Growth	-184.72%	-59.31%	-5.61%
Free Cash Flow Firm Growth	-172.14%	-70.51%	-3.88%
Invested Capital Growth	80.67%	-10.12%	-184.08%
Revenue Q/Q Growth	0.00%	0.00%	0.00%
EBITDA Q/Q Growth	-28.19%	-10.30%	1.05%
EBIT Q/Q Growth	-29.10%	-9.39%	1.69%
NOPAT Q/Q Growth	-26.59%	-11.71%	0.85%
Net Income Q/Q Growth	-27.03%	-12.35%	1.63%
EPS Q/Q Growth	-21.03%	-44.93%	32.80%
Operating Cash Flow Q/Q Growth	-31.11%	-5.90%	1.39%
Free Cash Flow Firm Q/Q Growth	-31.28%	-1.73%	-1.53%
Invested Capital Q/Q Growth	66.09%	-32.03%	23.67%
Profitability Metrics	-	-	-
Gross Margin	0.00%	0.00%	0.00%
EBITDA Margin	0.00%	0.00%	0.00%
Operating Margin	0.00%	0.00%	0.00%
EBIT Margin	0.00%	0.00%	0.00%
Profit (Net Income) Margin	0.00%	0.00%	0.00%
Tax Burden Percent	100.19%	102.80%	100.02%
Interest Burden Percent	101.47%	103.59%	101.92%
Effective Tax Rate	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%
Return on Equity (ROE)	-78.34%	-41.33%	-73.46%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	0.00%	0.00%	0.00%
Return on Assets (ROA)	0.00%	0.00%	0.00%
Return on Common Equity (ROCE)	-78.34%	-41.33%	-73.46%
Return on Equity Simple (ROE_SIMPLE)	-91.59%	-26.51%	-67.20%
Net Operating Profit after Tax (NOPAT)	-269	-106	-72
NOPAT Margin	0.00%	0.00%	0.00%
Net Nonoperating Expense Percent (NNEP)	-20.42%	-10.07%	-20.33%
Return On Investment Capital (ROIC_SIMPLE)	-61.68%	-18.86%	-41.61%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	0.00%	0.00%	0.00%
R&D to Revenue	0.00%	0.00%	0.00%
Operating Expenses to Revenue	0.00%	0.00%	0.00%
Earnings before Interest and Taxes (EBIT)	-361	-134	-100
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-370	-139	-100
Valuation Ratios	-	-	-
Price to Book Value (P/BV)	2.07	1.58	3.90
Price to Tangible Book Value (P/TBV)	2.07	1.58	3.90
Price to Revenue (P/Rev)	0.00	0.00	0.00
Price to Earnings (P/E)	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00
Leverage & Solvency	-	-	-
Debt to Equity	0.09	0.05	0.13
Long-Term Debt to Equity	0.09	0.05	0.13
Financial Leverage	-1.02	-1.05	-1.08
Leverage Ratio	1.15	1.15	1.29
Compound Leverage Factor	1.16	1.19	1.32
Debt to Total Capital	8.19%	4.42%	11.74%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	8.19%	4.42%	11.74%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%
Common Equity to Total Capital	91.81%	95.58%	88.26%
Debt to EBITDA	-0.10	-0.18	-0.20
Net Debt to EBITDA	1.09	3.99	1.68
Long-Term Debt to EBITDA	-0.10	-0.18	-0.20
Debt to NOPAT	-0.13	-0.23	-0.28
Net Debt to NOPAT	1.50	5.23	2.35
Long-Term Debt to NOPAT	-0.13	-0.23	-0.28
Altman Z-Score	2.60	7.78	5.03
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-
Current Ratio	13.19	20.04	7.97
Quick Ratio	12.18	19.55	7.64
Cash Flow Metrics	-	-	-
Free Cash Flow to Firm (FCFF)	-284	-104	-61
Operating Cash Flow to CapEx	-2,452,153.33%	-3,229,650.00%	-1,158,428.57%
Free Cash Flow to Firm to Interest Expense	-53.61	-21.74	-31.80
Operating Cash Flow to Interest Expense	-69.53	-26.95	-42.19
Operating Cash Flow Less CapEx to Interest Expense	-69.53	-26.95	-42.19
Efficiency Ratios	-	-	-
Asset Turnover	0.00	0.00	0.00
Accounts Receivable Turnover	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00
Fixed Asset Turnover	0.00	0.00	0.00
Accounts Payable Turnover	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-
Invested Capital	-3.43	-18	-16
Invested Capital Turnover	0.00	0.00	0.00
Increase / (Decrease) in Invested Capital	14	-1.63	-10
Enterprise Value (EV)	426	291	424
Market Capitalization	830	845	592
Book Value per Share	$3.78	$7.09	$3.26
Tangible Book Value per Share	$3.78	$7.09	$3.26
Total Capital	437	561	172
Total Debt	36	25	20
Total Long-Term Debt	36	25	20
Net Debt	-404	-554	-168
Capital Expenditures (CapEx)	0.02	0.00	0.01
Debt-free, Cash-free Net Working Capital (DFCFNWC)	0.37	-15	-17
Debt-free Net Working Capital (DFNWC)	440	564	171
Net Working Capital (NWC)	440	564	171
Net Nonoperating Expense (NNE)	98	36	30
Net Nonoperating Obligations (NNO)	-404	-554	-168
Total Depreciation and Amortization (D&A)	-9.10	-5.32	-0.15
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	0.00%	0.00%
Debt-free Net Working Capital to Revenue	0.00%	0.00%	0.00%
Net Working Capital to Revenue	0.00%	0.00%	0.00%
Earnings Adjustments	-	-	-
Adjusted Basic Earnings per Share	($3.51)	($2.00)	($2.93)
Adjusted Weighted Average Basic Shares Outstanding	104.71M	71.17M	34.81M
Adjusted Diluted Earnings per Share	($3.51)	($2.00)	($2.93)
Adjusted Weighted Average Diluted Shares Outstanding	104.71M	71.17M	34.81M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	145.98M	93.50M	52.23M
Normalized Net Operating Profit after Tax (NOPAT)	-269	-106	-72
Normalized NOPAT Margin	0.00%	0.00%	0.00%
Pre Tax Income Margin	0.00%	0.00%	0.00%
Debt Service Ratios	-	-	-
EBIT to Interest Expense	-68.26	-27.85	-52.07
NOPAT to Interest Expense	-50.90	-22.08	-37.24
EBIT Less CapEx to Interest Expense	-68.26	-27.85	-52.08
NOPAT Less CapEx to Interest Expense	-50.90	-22.08	-37.24
Payout Ratios	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%
Augmented Payout Ratio	-0.07%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from 89bio's official financial filings.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Growth	-33.60%	-218.52%	-317.69%	-28.56%	-93.60%	-53.39%	-34.50%	-56.63%	-10.52%	4.21%	4.98%
EBIT Growth	-37.76%	-229.29%	-333.89%	-25.24%	-89.53%	-47.67%	-28.54%	-52.31%	-6.38%	6.68%	7.28%
NOPAT Growth	-32.53%	-196.09%	-286.17%	-26.84%	-100.80%	-62.47%	-45.50%	-70.30%	-13.61%	3.35%	4.15%
Net Income Growth	-37.91%	-194.16%	-329.30%	-24.95%	-79.22%	-63.54%	-29.55%	-53.24%	-12.79%	6.41%	5.38%
EPS Growth	9.26%	-124.49%	-208.89%	7.69%	0.00%	-476.92%	21.05%	57.72%	57.14%	110.00%	59.57%
Operating Cash Flow Growth	-80.61%	-254.53%	-378.77%	-77.56%	-32.03%	-26.56%	-104.93%	-132.20%	-23.58%	4.05%	-10.15%
Free Cash Flow Firm Growth	-243.62%	-266.53%	-211.39%	-0.02%	-82.78%	-272.89%	-407.95%	-326.32%	-0.07%	49.26%	56.04%
Invested Capital Growth	109.77%	80.67%	24.74%	175.12%	-149.90%	-10.12%	36.34%	70.91%	-175.11%	-184.08%	-131.13%
Revenue Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Q/Q Growth	39.91%	20.26%	-201.43%	7.50%	-44.38%	-4.56%	7.22%	-39.29%	-13.51%	8.31%	-8.04%
EBIT Q/Q Growth	40.23%	20.20%	-211.96%	7.41%	-42.87%	-5.14%	9.95%	-40.13%	-11.31%	8.48%	-6.69%
NOPAT Q/Q Growth	37.78%	19.70%	-184.34%	6.71%	-39.00%	-4.73%	6.61%	-47.70%	-12.47%	6.21%	-9.31%
Net Income Q/Q Growth	39.78%	20.61%	-210.76%	7.18%	-28.45%	-15.87%	9.55%	-33.14%	-17.21%	8.22%	-6.99%
EPS Q/Q Growth	55.45%	20.86%	-189.58%	11.11%	-10.20%	-8.89%	13.46%	3.70%	-515.38%	122.81%	53.66%
Operating Cash Flow Q/Q Growth	41.00%	16.36%	-137.65%	-53.99%	-15.83%	-12.95%	11.86%	-14.50%	-11.03%	-82.90%	0.13%
Free Cash Flow Firm Q/Q Growth	17.24%	9.07%	-90.46%	-139.73%	11.72%	22.75%	38.82%	-338.11%	-80.10%	-5.23%	-127.26%
Invested Capital Q/Q Growth	176.24%	66.09%	-216.98%	132.32%	-50.78%	-32.03%	-16.76%	-7.51%	33.56%	23.67%	46.63%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBIT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Profit (Net Income) Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Tax Burden Percent	100.19%	100.22%	100.14%	100.28%	100.19%	110.63%	100.00%	100.00%	100.00%	100.07%	100.01%
Interest Burden Percent	101.81%	101.02%	101.61%	101.86%	101.70%	102.44%	102.84%	102.38%	107.75%	102.27%	102.04%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	-69.30%	-78.34%	-73.31%	-36.50%	-34.51%	-41.33%	-44.98%	-45.44%	-38.39%	-73.46%	-69.29%
Cash Return on Invested Capital (CROIC)	-11,906.48%	0.00%	0.00%	-1,779.50%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Assets (ROA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Common Equity (ROCE)	-69.30%	-78.34%	-73.31%	-36.50%	-34.51%	-41.33%	-44.98%	-45.44%	-38.39%	-73.46%	-69.29%
Return on Equity Simple (ROE_SIMPLE)	-63.86%	0.00%	-76.42%	-33.91%	-32.33%	0.00%	-30.85%	-26.84%	-23.62%	0.00%	-67.97%
Net Operating Profit after Tax (NOPAT)	-53	-85	-106	-37	-40	-29	-28	-29	-20	-18	-19
NOPAT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Nonoperating Expense Percent (NNEP)	-3.18%	-6.88%	-10.52%	-2.20%	-2.33%	-3.16%	-2.41%	-3.11%	-3.15%	-4.57%	-4.78%
Return On Investment Capital (ROIC_SIMPLE)	-8.28%	-19.56%	-	-	-	-5.14%	-	-	-	-10.32%	-
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings before Interest and Taxes (EBIT)	-70	-117	-147	-47	-51	-36	-34	-37	-27	-24	-26
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-71	-119	-149	-49	-53	-37	-36	-38	-28	-24	-26
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	1.75	2.07	2.07	1.53	2.13	1.58	2.84	3.12	1.78	3.90	1.48
Price to Tangible Book Value (P/TBV)	1.75	2.07	2.07	1.53	2.13	1.58	2.84	3.12	1.78	3.90	1.48
Price to Revenue (P/Rev)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	175.12	0.00	0.00	32.55	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.06	0.09	0.09	0.05	0.05	0.05	0.06	0.06	0.05	0.13	0.13
Long-Term Debt to Equity	0.06	0.09	0.09	0.04	0.05	0.05	0.06	0.06	0.05	0.13	0.08
Financial Leverage	-1.02	-1.02	-1.03	-1.00	-1.04	-1.05	-1.06	-1.10	-1.03	-1.08	-1.10
Leverage Ratio	1.13	1.15	1.17	1.12	1.12	1.15	1.17	1.23	1.15	1.29	1.23
Compound Leverage Factor	1.15	1.16	1.18	1.14	1.14	1.18	1.21	1.26	1.24	1.32	1.26
Debt to Total Capital	5.60%	8.19%	8.59%	4.65%	4.66%	4.42%	5.67%	5.25%	5.18%	11.74%	11.40%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.88%	0.35%	0.00%	0.00%	0.00%	0.00%	0.00%	3.87%
Long-Term Debt to Total Capital	5.60%	8.19%	8.59%	3.77%	4.31%	4.42%	5.67%	5.25%	5.18%	11.74%	7.53%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	94.40%	91.81%	91.41%	95.35%	95.34%	95.58%	94.33%	94.75%	94.82%	88.26%	88.60%
Debt to EBITDA	-0.09	-0.10	-0.12	-0.14	-0.15	-0.18	-0.20	-0.21	-0.24	-0.20	-0.19
Net Debt to EBITDA	1.55	1.09	1.34	2.88	3.26	3.99	3.37	3.88	4.44	1.68	1.71
Long-Term Debt to EBITDA	-0.09	-0.10	-0.12	-0.12	-0.14	-0.18	-0.20	-0.21	-0.24	-0.20	-0.13
Debt to NOPAT	-0.13	-0.13	-0.17	-0.19	-0.20	-0.23	-0.26	-0.28	-0.33	-0.28	-0.27
Net Debt to NOPAT	2.14	1.50	1.83	3.78	4.27	5.23	4.47	5.26	6.17	2.35	2.41
Long-Term Debt to NOPAT	-0.13	-0.13	-0.17	-0.15	-0.18	-0.23	-0.26	-0.28	-0.33	-0.28	-0.18
Altman Z-Score	6.97	4.28	3.74	6.54	9.37	8.32	13.63	16.19	9.83	6.30	1.36
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	18.03	13.19	11.66	13.92	15.03	20.04	18.23	18.96	20.56	7.97	5.81
Quick Ratio	16.86	12.18	10.83	12.76	14.70	19.55	17.78	18.42	20.02	7.64	5.62
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-83	-100	-110	-58	-24	-27	-35	-58	-13	-7.30	-6.93
Operating Cash Flow to CapEx	-99,634.72%	-810,533.33%	0.00%	0.00%	0.00%	-857,325.00%	0.00%	0.00%	0.00%	-1,354,800.00%	0.00%
Free Cash Flow to Firm to Interest Expense	-65.15	-83.74	-46.44	-65.89	-27.84	-31.42	-36.73	-64.41	-6.33	-13.39	-12.96
Operating Cash Flow to Interest Expense	-56.62	-102.08	-61.54	-69.98	-46.03	-39.60	-31.66	-38.53	-14.50	-49.72	-27.69
Operating Cash Flow Less CapEx to Interest Expense	-56.68	-102.09	-61.54	-69.98	-46.03	-39.60	-31.66	-38.53	-14.50	-49.72	-27.69
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Accounts Receivable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	2.62	-3.43	-10	8.66	-27	-18	-13	-12	-11	-16	-21
Invested Capital Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Increase / (Decrease) in Invested Capital	29	14	3.33	20	-16	-1.63	7.68	28	-6.82	-10	-12
Enterprise Value (EV)	458	426	396	282	551	291	742	927	339	424	53
Market Capitalization	1,061	830	784	788	1,088	845	1,165	1,381	795	592	226
Book Value per Share	$4.15	$3.78	$3.57	$5.23	$5.46	$7.09	$5.43	$6.07	$8.54	$3.26	$3.90
Tangible Book Value per Share	$4.15	$3.78	$3.57	$5.23	$5.46	$7.09	$5.43	$6.07	$8.54	$3.26	$3.90
Total Capital	641	437	414	540	535	561	435	466	470	172	172
Total Debt	36	36	36	25	25	25	25	24	24	20	20
Total Long-Term Debt	36	36	36	20	23	25	25	24	24	20	13
Net Debt	-603	-404	-388	-506	-537	-554	-424	-454	-457	-168	-174
Capital Expenditures (CapEx)	0.07	0.02	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)	6.28	0.37	-6.70	12	-24	-15	-14	-12	-11	-17	-21
Debt-free Net Working Capital (DFNWC)	645	440	417	543	538	564	434	466	470	171	172
Net Working Capital (NWC)	645	440	417	538	537	564	434	466	470	171	165
Net Nonoperating Expense (NNE)	18	33	43	11	12	11	7.18	8.90	8.87	6.85	7.88
Net Nonoperating Obligations (NNO)	-603	-404	-388	-506	-537	-554	-424	-454	-457	-168	-174
Total Depreciation and Amortization (D&A)	-1.43	-1.75	-2.30	-2.40	-2.65	-1.75	-1.86	-0.90	-0.81	-0.25	-0.22
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Debt-free Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.49)	($1.10)	($1.39)	($0.48)	($0.54)	($0.49)	($0.45)	($0.52)	($0.54)	$0.13	($0.57)
Adjusted Weighted Average Basic Shares Outstanding	146.37M	104.71M	107.08M	99.83M	95.85M	71.17M	76.34M	74.13M	53.17M	34.81M	47.25M
Adjusted Diluted Earnings per Share	($0.49)	($1.10)	($1.39)	($0.48)	($0.54)	($0.49)	($0.45)	($0.52)	($0.54)	$0.13	($0.57)
Adjusted Weighted Average Diluted Shares Outstanding	146.37M	104.71M	107.08M	99.83M	95.85M	71.17M	76.34M	74.13M	53.17M	34.81M	47.25M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	145.98M	145.98M	106.13M	105.91M	98.38M	93.50M	75.64M	75.48M	72.87M	52.23M	46.54M
Normalized Net Operating Profit after Tax (NOPAT)	-53	-85	-106	-37	-40	-29	-28	-29	-20	-18	-19
Normalized NOPAT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Pre Tax Income Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-55.15	-98.16	-62.03	-53.73	-58.77	-41.00	-35.21	-41.95	-12.90	-44.11	-49.10
NOPAT to Interest Expense	-41.94	-71.71	-45.03	-42.80	-46.46	-33.31	-28.72	-32.99	-9.62	-32.58	-35.38
EBIT Less CapEx to Interest Expense	-55.20	-98.17	-62.03	-53.73	-58.77	-41.00	-35.21	-41.95	-12.90	-44.12	-49.10
NOPAT Less CapEx to Interest Expense	-42.00	-71.72	-45.03	-42.80	-46.46	-33.31	-28.72	-32.99	-9.62	-32.58	-35.38
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	-0.07%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About 89bio's Financials

When does 89bio's fiscal year end?

According to the most recent income statement we have on file, 89bio's financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has 89bio's net income changed over the last 2 years?

89bio's net income appears to be on an upward trend, with a most recent value of -$367.08 million in 2024, rising from -$102.03 million in 2022. The previous period was -$142.19 million in 2023. See 89bio's forecast for analyst expectations on what’s next for the company.

What is 89bio's operating income?

89bio's total operating income in 2024 was -$384.66 million, based on the following breakdown:

Total Gross Profit: $0.00
Total Operating Expenses: $384.66 million

How has 89bio revenue changed over the last 2 years?

Over the last 2 years, 89bio's total revenue changed from $0.00 in 2022 to $0.00 in 2024, a change of 0.0%.

How much debt does 89bio have?

89bio's total liabilities were at $77.90 million at the end of 2024, a 29.9% increase from 2023, and a 73.1% increase since 2022.

How much cash does 89bio have?

In the past 2 years, 89bio's cash and equivalents has ranged from $55.26 million in 2022 to $316.16 million in 2023, and is currently $126.06 million as of their latest financial filing in 2024.

How has 89bio's book value per share changed over the last 2 years?

Over the last 2 years, 89bio's book value per share changed from 3.26 in 2022 to 3.78 in 2024, a change of 15.8%.

Related Companies

This page (NASDAQ:ETNB) was last updated on 5/21/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

89bio (ETNB) Financials

Frequently Asked Questions About 89bio's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

89bio (ETNB) Financials

Annual Income Statements for 89bio

Quarterly Income Statements for 89bio

Annual Cash Flow Statements for 89bio

Quarterly Cash Flow Statements for 89bio

Annual Balance Sheets for 89bio

Quarterly Balance Sheets for 89bio

Annual Metrics And Ratios for 89bio

Quarterly Metrics And Ratios for 89bio

Frequently Asked Questions About 89bio's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools